{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:56:24Z","timestamp":1790456184541,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics Inc","doi-asserted-by":"publisher","award":["KOROST25G0"],"award-info":[{"award-number":["KOROST25G0"]}],"id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-18-CE14\\u20130004"],"award-info":[{"award-number":["ANR-18-CE14\\u20130004"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R35GM127094"],"award-info":[{"award-number":["5R35GM127094"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL153988"],"award-info":[{"award-number":["R01 HL153988"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32HL171029"],"award-info":[{"award-number":["T32HL171029"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcf.2026.02.014","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T20:34:13Z","timestamp":1772570053000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic approaches for nonsense mutations in CFTR"],"prefix":"10.1016","author":[{"given":"Mairead","family":"Kelly-Aubert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0281-1686","authenticated-orcid":false,"given":"Kari","family":"Thrasher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1588-717X","authenticated-orcid":false,"given":"Andrei A.","family":"Korostelev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1820-711X","authenticated-orcid":false,"given":"John D.","family":"Lueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5537-9482","authenticated-orcid":false,"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.02.014_bib0001","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/humu.20763","article-title":"A meta-analysis of nonsense mutations causing human genetic disease","volume":"29","author":"Mort","year":"2008","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jcf.2026.02.014_bib0002","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2023.02.009","article-title":"Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020","volume":"22","author":"Cromwell","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.02.014_bib0003","unstructured":"Marshall, B. et al. Cystic fibrosis foundation patient registry 2014 annual data report. Bethesda, Md.https:\/\/www.cffamilyconnection.org\/wp-content\/uploads\/2016\/03\/2014_CFF-_Annual_Data_Report_to_the_Center_Directors.pdf."},{"key":"10.1016\/j.jcf.2026.02.014_bib0004","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.prrv.2013.01.006","article-title":"team, C. CFTR2: how will it help care?","volume":"14","author":"Castellani","year":"2013","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jcf.2026.02.014_bib0005","doi-asserted-by":"crossref","unstructured":"Pranke, I., Golec, A., Hinzpeter, A., Edelman, A. & Sermet-Gaudelus, I. Emerging therapeutic approaches for cystic fibrosis. From gene editing to personalized medicine. Front Pharmacol 10, 121, doi:10.3389\/fphar.2019.00121 (2019).","DOI":"10.3389\/fphar.2019.00121"},{"key":"10.1016\/j.jcf.2026.02.014_bib0006","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1215040","article-title":"A systematic survey of loss-of-function variants in human protein-coding genes","volume":"335","author":"MacArthur","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jcf.2026.02.014_bib0007","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jcf.2023.06.005","article-title":"Nonsense mutations accelerate lung disease and decrease survival of cystic fibrosis children","volume":"22","author":"Orenti","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.02.014_bib0008","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/ng1429","article-title":"Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise","volume":"36","author":"Mendell","year":"2004","journal-title":"Nat Genet"},{"key":"10.1016\/j.jcf.2026.02.014_bib0009","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/sj.gt.3302211","article-title":"Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment","volume":"11","author":"Bidou","year":"2004","journal-title":"Gene Ther"},{"key":"10.1016\/j.jcf.2026.02.014_bib0010","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI28523","article-title":"Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin","volume":"117","author":"Linde","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2026.02.014_bib0011","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/humu.22236","article-title":"Alternative splicing of in-frame exon associated with premature termination codons: implications for readthrough therapies","volume":"34","author":"Hinzpeter","year":"2013","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jcf.2026.02.014_bib0012","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/hmg\/8.10.1893","article-title":"Nonsense-mediated mRNA decay in health and disease","volume":"8","author":"Frischmeyer","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jcf.2026.02.014_bib0013","first-page":"453","article-title":"When cells stop making sense: effects of nonsense codons on RNA metabolism in vertebrate cells","volume":"1","author":"Maquat","year":"1995","journal-title":"Rna"},{"key":"10.1016\/j.jcf.2026.02.014_bib0014","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrm1310","article-title":"Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics","volume":"5","author":"Maquat","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jcf.2026.02.014_bib0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev.biochem.76.050106.093909","article-title":"The nonsense-mediated decay RNA surveillance pathway","volume":"76","author":"Chang","year":"2007","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jcf.2026.02.014_bib0016","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molmed.2023.01.004","article-title":"Readthrough compounds for nonsense mutations: bridging the translational gap","volume":"29","author":"Spelier","year":"2023","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jcf.2026.02.014_bib0017","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3390\/biom13060988","article-title":"Pharmaceuticals promoting premature termination codon readthrough: progress in development","volume":"13","author":"Li","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.jcf.2026.02.014_bib0018","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1164\/rccm.201605-1021ED","article-title":"New pharmacological approaches to treat patients with cystic fibrosis with nonsense mutations","volume":"194","author":"Sermet-Gaudelus","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.02.014_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111972","article-title":"Comprehensive analysis of combinatorial pharmacological treatments to correct nonsense mutations in the CFTR gene","volume":"22","author":"Venturini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2026.02.014_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1389586","article-title":"Readthrough-induced misincorporated amino acid ratios guide mutant-specific therapeutic approaches for two CFTR nonsense mutations","volume":"15","author":"Premchandar","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2026.02.014_bib0021","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jcf.2024.07.017","article-title":"TLN468 changes the pattern of tRNA used to read through premature termination codons in CFTR","volume":"23","author":"Karri","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.02.014_bib0022","first-page":"1433","volume":"349","author":"Wilschanski","year":"2003"},{"key":"10.1016\/j.jcf.2026.02.014_bib0023","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1741-7015-5-5","article-title":"In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study","volume":"5","author":"Sermet-Gaudelus","year":"2007","journal-title":"BMC Med"},{"key":"10.1016\/j.jcf.2026.02.014_bib0024","first-page":"12508","article-title":"Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression","volume":"113","author":"Roy","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America (PNAS)"},{"key":"10.1016\/j.jcf.2026.02.014_bib0025","article-title":"PTC therapeutics announces results from pivotal phase 3 clinical trial of ataluren in patients living with nonsense mutation cystic fibrosis","author":"Therapeutics","year":"2017","journal-title":"PR News-wire"},{"key":"10.1016\/j.jcf.2026.02.014_bib0026","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2021.01.009","article-title":"Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids","volume":"20","author":"Crawford","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.02.014_bib0027","unstructured":"(Globe Newswire, 2023)."},{"key":"10.1016\/j.jcf.2026.02.014_bib0028","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41467-020-15140-z","article-title":"2, 6-Diaminopurine as a highly potent corrector of UGA nonsense mutations","volume":"11","author":"Trzaska","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcf.2026.02.014_bib0029","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.ymthe.2023.01.014","article-title":"Use of 2, 6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis","volume":"31","author":"Leroy","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcf.2026.02.014_bib0030","first-page":"132","article-title":"Small-molecule eRF3a degraders rescue CFTR nonsense mutations by promoting premature termination codon readthrough","author":"Lee","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2026.02.014_bib0031","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1093\/nar\/gkab194","article-title":"Effect of small molecule eRF3 degraders on premature termination codon readthrough","volume":"49","author":"Baradaran-Heravi","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jcf.2026.02.014_bib0032","first-page":"11","article-title":"Identifying potent nonsense-mediated mRNA decay inhibitors with a novel screening system","author":"Carrard","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jcf.2026.02.014_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108919","article-title":"Suppressor tRNAs as personalized therapy for nonsense mutation-associated pathologies","volume":"274","author":"Ignatova","year":"2025","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jcf.2026.02.014_bib0034","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41573-023-00829-9","article-title":"tRNA therapeutics for genetic diseases","volume":"23","author":"Coller","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcf.2026.02.014_bib0035","doi-asserted-by":"crossref","first-page":"e1641","DOI":"10.1002\/wrna.1641","article-title":"Therapeutic promise of engineered nonsense suppressor tRNAs","volume":"12","author":"Porter","year":"2021","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"10.1016\/j.jcf.2026.02.014_bib0036","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/296537a0","article-title":"Construction of a functional human suppressor tRNA gene: an approach to gene therapy for beta-thalassaemia","volume":"296","author":"Temple","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.jcf.2026.02.014_bib0037","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41467-019-08329-4","article-title":"Engineered transfer RNAs for suppression of premature termination codons","volume":"10","author":"Lueck","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcf.2026.02.014_bib0038","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41586-022-04533-3","article-title":"AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice","volume":"604","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jcf.2026.02.014_bib0039","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-023-06133-1","article-title":"Engineered tRNAs suppress nonsense mutations in cells and in vivo","author":"Albers","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jcf.2026.02.014_bib0040","doi-asserted-by":"crossref","first-page":"14244","DOI":"10.1093\/nar\/gkae1048","article-title":"Efficient suppression of premature termination codons with alanine by engineered chimeric pyrrolysine tRNAs","volume":"52","author":"Awawdeh","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jcf.2026.02.014_bib0041","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkae1112","article-title":"Optimization of ACE-tRNAs function in translation for suppression of nonsense mutations","author":"Porter","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jcf.2026.02.014_bib0042","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.omtn.2022.04.033","article-title":"Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs","volume":"28","author":"Ko","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jcf.2026.02.014_bib0043","first-page":"53","article-title":"ACE-tRNAs are a platform technology for suppressing nonsense mutations that cause cystic fibrosis","author":"Ko","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jcf.2026.02.014_bib0044","first-page":"53","article-title":"An engineered glutamic acid tRNA for efficient suppression of pathogenic nonsense mutations","author":"Specht","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jcf.2026.02.014_bib0045","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1021\/acsnano.4c11858","article-title":"Emerging delivery systems for enabling precision nucleic acid therapeutics","volume":"19","author":"Bian","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.jcf.2026.02.014_bib0046","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1128\/MCB.20.9.3116-3124.2000","article-title":"Suppression of nonsense mutations in cell culture and mice by multimerized suppressor tRNA genes","volume":"20","author":"Buvoli","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jcf.2026.02.014_bib0047","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jcf.2026.02.014_bib0048","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkag082","article-title":"Anticodon edited transfer RNAs (ACE-tRNAs) encoded as therapeutic nonviral minimal DNA vectors","author":"Porter","year":"2026","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jcf.2026.02.014_bib0049","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70447","article-title":"Revolution of AAV in drug discovery: from delivery system to clinical application","volume":"97","author":"Yin","year":"2025","journal-title":"J Med Virol"},{"key":"10.1016\/j.jcf.2026.02.014_bib0050","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.ymthe.2025.03.056","article-title":"Advances in AAV capsid engineering: integrating rational design, directed evolution and machine learning","volume":"33","author":"Nisanov","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcf.2026.02.014_bib0051","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41586-025-09732-2","article-title":"Prime editing-installed suppressor tRNAs for disease-agnostic genome editing","volume":"648","author":"Pierce","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jcf.2026.02.014_bib0052","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jcf.2026.02.014_bib0053","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.1093\/nar\/gkae624","article-title":"mRNA-specific readthrough of nonsense codons by antisense oligonucleotides (R-ASOs)","volume":"52","author":"Susorov","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jcf.2026.02.014_bib0054","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev-biochem-071921-122857","article-title":"The structural dynamics of translation","volume":"91","author":"Korostelev","year":"2022","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jcf.2026.02.014_bib0055","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1016\/j.cell.2024.10.035","article-title":"The ribosome comes to life","volume":"187","author":"Noller","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.jcf.2026.02.014_bib0056","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-biochem-113009-092313","article-title":"Structural basis of the translational elongation cycle","volume":"82","author":"Voorhees","year":"2013","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jcf.2026.02.014_bib0057","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2016.10.046","article-title":"Decoding mammalian ribosome-mRNA states by translational GTPase complexes","volume":"167","author":"Shao","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jcf.2026.02.014_bib0058","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1126\/science.aai9127","article-title":"Translational termination without a stop codon","volume":"354","author":"James","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jcf.2026.02.014_bib0059","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1073\/pnas.92.12.5431","article-title":"Translational termination efficiency in mammals is influenced by the base following the stop codon","volume":"92","author":"McCaughan","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcf.2026.02.014_bib0060","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/j.1460-2075.1995.tb06985.x","article-title":"The identity of the base following the stop codon determines the efficiency of in vivo translational termination in Escherichia coli","volume":"14","author":"Poole","year":"1995","journal-title":"Embo j"},{"key":"10.1016\/j.jcf.2026.02.014_bib0061","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1261\/rna.076588.120","article-title":"Termi-Luc: a versatile assay to monitor full-protein release from ribosomes","volume":"26","author":"Susorov","year":"2020","journal-title":"Rna"},{"key":"10.1016\/j.jcf.2026.02.014_bib0062","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.molcel.2022.11.011","article-title":"CRISPR-free, programmable RNA pseudouridylation to suppress premature termination codons","volume":"83","author":"Song","year":"2023","journal-title":"Mol Cell"},{"key":"10.1016\/j.jcf.2026.02.014_bib0063","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.molcel.2023.01.009","article-title":"Targeted pseudouridylation: an approach for suppressing nonsense mutations in disease genes","volume":"83","author":"Adachi","year":"2023","journal-title":"Mol Cell"},{"key":"10.1016\/j.jcf.2026.02.014_bib0064","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41587-024-02165-8","article-title":"Near-cognate tRNAs increase the efficiency and precision of pseudouridine-mediated readthrough of premature termination codons","volume":"43","author":"Luo","year":"2025","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcf.2026.02.014_bib0065","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52611","article-title":"Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides","volume":"9","author":"Wangen","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.jcf.2026.02.014_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105246","article-title":"Ushering in the era of tRNA medicines","volume":"299","author":"Anastassiadis","year":"2023","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcf.2026.02.014_bib0067","first-page":"62","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","author":"Dreano","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.02.014_bib0068","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nbt.3427","article-title":"Antisense oligonucleotide\u2013directed inhibition of nonsense-mediated mRNA decay","volume":"34","author":"Nomakuchi","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcf.2026.02.014_bib0069","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1750-1172-7-58","article-title":"Rescue of nonsense mutations by amlexanox in human cells","volume":"7","author":"Gonzalez-Hilarion","year":"2012","journal-title":"Orphanet J Rare Dis"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:13:37Z","timestamp":1778822017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326000433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":69,"alternative-id":["S1569199326000433"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.02.014","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic approaches for nonsense mutations in CFTR","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}